Training & Competency for AI Teams


Published on 02/12/2025

Training & Competency for AI Teams: A Step-by-Step Guide

Introduction to AI/ML Model Validation in GxP Analytics

The integration of Artificial Intelligence (AI) and Machine Learning (ML) into Good Practice (GxP) analytics has transformed pharmaceutical processes, enabling innovative solutions that enhance efficiency and accuracy. However, the deployment of AI/ML models within regulated environments necessitates a rigorous training and competency framework to address various regulatory expectations, including those outlined by the FDA, EMA, and MHRA. This tutorial aims to provide a step-by-step guide for pharmaceutical professionals focusing on the validation of AI/ML models, emphasizing risk management, explainability, drift monitoring, and compliance with documentation requirements.

Step 1: Understanding Intended Use and Risk Assessment

The first step in AI/ML model validation is to articulate the intended use of the model clearly. Defining the intended use helps identify the scope and potential risks associated with model deployment. This process includes the following sub-steps:

  • Identify the Application: Determine where and how the AI/ML model will be used within the pharmaceutical lifecycle, such as drug discovery, clinical trials, or post-market surveillance.
  • Risk Analysis: Conduct a thorough risk analysis to identify and evaluate the risks related to model failure or misprediction, which could impact patient safety, data integrity, and regulatory compliance.
  • Documentation of Intended Use: Maintain clear documentation regarding the intended use of the AI/ML model, ensuring it aligns with regulatory definitions and expectations, notably under 21 CFR Part 11 and Annex 11.

Step 2: Data Readiness and Curation

Data readiness is crucial for the successful deployment of AI/ML models, as the quality of input data directly affects model performance and reliability. This phase involves several critical actions:

  • Data Collection: Gather data from various sources, ensuring it represents the population intended for modeling. Data should be diverse enough to minimize biases.
  • Data Cleaning and Preprocessing: Implement robust data cleaning procedures to remove duplicates, handle missing values, and eliminate outliers that could adversely affect model training.
  • Bias Mitigation: Conduct a bias analysis to identify and address any biases within the data that may influence model outcomes, particularly those affecting underrepresented populations.
  • Documentation: Maintain a detailed record of data sources, cleaning methodologies, and decisions made during the data curation process.

Step 3: Model Development and Verification

With data prepared, the next step is the development of the AI/ML model. This phase consists of systematic approaches for model selection, training, and initial validation:

  • Model Selection: Choose the appropriate algorithm based on the problem at hand, whether it be supervised learning for classifications or unsupervised learning for clustering.
  • Training the Model: Utilize the curated data set to train the model, ensuring that you apply best practices to avoid overfitting and underfitting.
  • Initial Model Verification: Validate the model using techniques such as cross-validation and holdout methods to ensure generalizability.
  • Performance Metrics: Define relevant performance metrics to evaluate model effectiveness, including accuracy, precision, recall, and F1 score. This enables quantifiable assessments of model behavior.

Step 4: Validation and Robustness Testing

Following initial verification, the model must undergo comprehensive validation to ensure its robustness and reliability in a regulated environment:

  • Full Model Validation: Conduct a thorough verification and validation (V&V) process to confirm that the model performs as intended across different scenarios and datasets.
  • Explainability Testing: Integrate Explainable AI (XAI) principles to provide insights into model decision-making processes, critical for meeting regulatory expectations and gaining stakeholder trust.
  • Documentation of V&V Activities: Maintain meticulous documentation of all V&V activities, including methodologies, results, and any deviations from expected outcomes.

Step 5: Drift Monitoring and Re-validation

The pharmaceutical environment is subject to changes that may affect model performance over time. Continuous monitoring and potential re-validation are essential components of AI/ML governance:

  • Define Drift Metrics: Establish metrics to quantify model drift, which refers to the degradation in predictive performance over time.
  • Ongoing Performance Monitoring: Implement systems for ongoing data collection and monitoring to identify drift and initiate timely investigations into anomalies.
  • Re-validation Protocols: Define a clear protocol for re-validation when drift is detected or when new data becomes available, ensuring compliance with regulatory requirements.

Step 6: Documentation and Audit Trails

Thorough documentation and maintaining audit trails are paramount for regulatory compliance, risk mitigation, and quality assurance:

  • Document Development Processes: Keep comprehensive records of model development, including decisions made, data used, and results obtained during training, verification, and validation.
  • Audit Trail Maintenance: Ensure that all changes to the model, data, and processes are recorded and retrievable, aligning with 21 CFR Part 11 requirements for electronic records and signatures.
  • Regular Documentation Reviews: Institute a regular review process for documentation to ensure all entries are up-to-date, accurate, and reflective of current practices.

Step 7: AI Governance and Security Framework

Lastly, establishing an AI governance and security framework is essential for ensuring that AI/ML systems are effectively managed and compliant with regulatory standards:

  • Governance Structures: Create governance structures within the organization that define roles, responsibilities, and workflows for managing AI/ML risks, including compliance with GAMP 5 guidelines.
  • Security Measures: Implement robust security measures to protect data integrity and availability, ensuring compliance with relevant industry standards and regulations.
  • Training and Competency Development: Promote ongoing training and competency development for team members involved in AI/ML model validation, ensuring they remain abreast of the latest regulatory expectations and technological advancements.

Conclusion

The validation of AI/ML models within GxP analytics is a critical undertaking requiring rigorous attention to risk management, explainability, documentation, and compliance with regulatory standards. By following the structured approach outlined in this guide, pharmaceutical professionals can establish the necessary frameworks to support the safe and effective integration of AI/ML technologies into their operations, ultimately enhancing patient safety and maintaining data integrity.